Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
54.65
+9.47 (20.96%)
At close: Mar 6, 2026

HKG:2315 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1,379980.45716.91533.88354.56
Revenue Growth (YoY)
40.63%36.76%34.28%50.58%39.84%
Cost of Revenue
-204.74206138.2197.3
Gross Profit
1,379775.71510.91395.67257.25
Selling, General & Admin
-311.35349.09313.66230.15
Research & Development
438.05323.93474.37699.17558.49
Other Operating Expenses
752.17-9.72-21.04-12.56-12.32
Operating Expenses
1,190625.56802.411,000776.32
Operating Income
188.58150.16-291.5-604.6-519.07
Interest Expense
--91.68-99.84-56.14-39.43
Interest & Investment Income
-5.910.162.1712.51
Earnings From Equity Investments
--29.75-10.03-14.77-0.4
Currency Exchange Gain (Loss)
-8.679.0827.37-1.78
Other Non Operating Income (Expenses)
-0.55----
EBT Excluding Unusual Items
188.0343.29-382.14-645.97-548.16
Gain (Loss) on Sale of Investments
--0.360.1519.272.13
Gain (Loss) on Sale of Assets
-0.011.8325.350.39
Pretax Income
188.0342.94-380.16-601.35-545.64
Income Tax Expense
14.839.42.80.8-
Earnings From Continuing Operations
173.233.54-382.95-602.16-545.64
Minority Interest in Earnings
-0.0100.210.07
Net Income
173.233.54-382.95-601.95-545.58
Net Income to Common
173.233.54-382.95-601.95-545.58
Net Income Growth
416.37%----
Shares Outstanding (Basic)
403398398381362
Shares Outstanding (Diluted)
403398398381362
Shares Change (YoY)
1.20%-0.08%4.54%5.13%180.82%
EPS (Basic)
0.430.08-0.96-1.58-1.51
EPS (Diluted)
0.430.08-0.96-1.58-1.51
EPS Growth
410.24%----
Free Cash Flow
-174.12-203.26-543.54-564.45
Free Cash Flow Per Share
-0.44-0.51-1.43-1.56
Gross Margin
100.00%79.12%71.27%74.11%72.56%
Operating Margin
13.68%15.32%-40.66%-113.25%-146.40%
Profit Margin
12.56%3.42%-53.42%-112.75%-153.88%
Free Cash Flow Margin
-17.76%-28.35%-101.81%-159.20%
EBITDA
327.47289.05-154.78-465.86-415.47
EBITDA Margin
23.75%29.48%-21.59%-87.26%-117.18%
D&A For EBITDA
138.89138.89136.73138.74103.6
EBIT
188.58150.16-291.5-604.6-519.07
EBIT Margin
13.68%15.32%-40.66%-113.25%-146.40%
Effective Tax Rate
7.89%21.90%---
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.